Prostate Cancer Misdiagnosis Elimination Act of 2016
Official title: To clarify the treatment of certain DNA Specimen Provenance Assay tests as reasonable and necessary for the diagnosis or treatment of illness for coverage under the Medicare program.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Prostate Cancer Misdiagnosis Elimination Act of 2016
This bill specifies that, unless the physician ordering a DNA Specimen Provenance Assay (DSPA) test recommends otherwise, a DSPA test furnished with respect to a positive prostate cancer biopsy shall be deemed to be medically necessary for purposes of Medicare.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 5763: Prostate Cancer Misdiagnosis Elimination Act of 2016. 114th Congress. Open America. https://openamerica.io/bill/114-HR-5763/
"H.R. 5763: Prostate Cancer Misdiagnosis Elimination Act of 2016." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-5763/.
H.R. 5763, 114th Cong. (2026), https://openamerica.io/bill/114-HR-5763/.
[H.R. 5763: Prostate Cancer Misdiagnosis Elimination Act of 2016](https://openamerica.io/bill/114-HR-5763/)